

ANALYSIS OF NON-BLEEDING UTERINE FIBROIDS SYMPTOM (NBUFSQ) QUESTIONNAIRE
 DURING TREATMENT AND POST-TREATMENT FOLLOW-UP PERIODS
 (MODIFIED INTENT-TO-TREAT ANALYSIS SET - COHORT 1)

VARIABLE	TIME POINT	TREATMENT	N	BASE MEAN	VISIT MEAN	WITHIN GROUP ----- CHANGE FROM BASELINE -----			MODEL-BASED BETWEEN GROUP COMPARISON ----- COMPARE TO PLACEBO -----				P-VALUE \$
						MEAN	SD	95% CI	DIFFERENCE OF LS		95% CI		
								LS MEANS (SE)	MEANS (SE)				
SUM OF SCORES OF Q1 TO Q6													
	BASELINE												
	PLACEBO		32		16.2			16.2 (2.22)					
	ELAGOLIX 300 MG BID		32		16.7			16.7 (2.22)	0.5 (3.14)	(-5.74, 6.69)		0.880	
	ELAGOLIX 300 MG BID +E2/NETA (LD)		32		11.3			11.3 (2.22)	-4.9 (3.14)	(-11.15, 1.29)		0.119	
	ELAGOLIX 300 MG BID +E2/NETA (SD)		29		17.5			17.5 (2.33)	1.3 (3.22)	(-5.11, 7.64)		0.695	

FINAL MONTH #

PLACEBO	37	16.2	10.9	-5.3	13.19	(-10.04, -0.53)	-5.0 (1.81)			
ELAGOLIX 300 MG BID	34	16.7	8.7	-6.7	11.94	(-11.11, -2.35)	-6.5 (1.84)	-1.5 (2.58)	(-6.65, 3.59)	0.556
ELAGOLIX 300 MG BID										
+E2/NETA (LD)	33	11.6	7.1	-4.1	10.15	(-7.92, -0.34)	-6.1 (1.90)	-1.1 (2.63)	(-6.33, 4.09)	0.672
ELAGOLIX 300 MG BID										
+E2/NETA (SD)	31	18.0	16.6	-3.5	12.59	(-8.58, 1.59)	-2.0 (2.02)	3.0 (2.71)	(-2.39, 8.36)	0.274